Follicular thyroid cancer pathophysiology

	Follicular thyroid cancer Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Follicular thyroid cancer from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
X-ray
Echocardiography and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Follicular thyroid cancer pathophysiology On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Follicular thyroid cancer pathophysiology All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Follicular thyroid cancer pathophysiology
CDC on Follicular thyroid cancer pathophysiology
Follicular thyroid cancer pathophysiology in the news
Blogs on Follicular thyroid cancer pathophysiology
Directions to Hospitals Treating Follicular thyroid cancer
Risk calculators and risk factors for Follicular thyroid cancer pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Follicular thyroid cancer is the second most common type of cancer. It constitute about 15% of thyroid cancers.
This occurs more commonly in women of over 50 years old. Thyroglobulin (Tg) can be used as a tumor marker for well-differentiated follicular thyroid cancer. Follicular carcinoma tends to metastasize to the lungs and bone via the bloodstream, while papillary thyroid carcinoma commonly metastasizes to cervical lymph nodes.Unlike papillary it metastasises late to lymph nodes, with only 5-10% of patients having nodal metastases at the time of diagnosis. Haematogenous spread is however much more common with 20% or so of patients having distant haematogenous metastases at presentation.

The Ras oncogene is positive in a significant proportion of individuals. Ras oncogene act through the RAF-MEK-MAPK kinase pathway.
Other genes involved in the pathogenesis of follicular thyroid cancer are as follows.

HRAS, KRAS, NRAS (mutation) associated with MAPK and PI3K-AKT signaling pathways

PAX8/PPARγ (translocation) associated with PAX8-associated nuclear transcription signaling pathways. PAX8 is responsible for follicular cell differentiation.

IDH1 (mutation) assciated with IDH1-associated metabolic pathways signaling pathways
Phosphatase and tensin homologue suppressor gene and the phosphatidylinositol 3-kinase pathway are also involved in the pathogenesis of follicular thyroid tumor.
p53, c-myc, c-fos, and the thyrotropin (TSH) receptor are some other factors involved in the pathogenesis of follicular thyroid cancer.
MicroRNAs namely miR-192, miR-197, miR-328, and miR-346 have increased expression in follicular cell carcinoma.

It is not possible to distinguish between follicular adenoma and carcinoma on cytological grounds. If fine needle aspiration cytology (FNAC) suggests follicular neoplasm, thyroid lobectomy should be performed to establish the histopathological diagnosis.
Trabecular, solid, follicular tumor cells that invade tumor capsule or surrounding vascular structures.

Thyroid, total thyroidectomy. Widely invasive follicular carcinoma, 4.5 cm, with lymphovascular invasion and extracapsular extension. Negative margins
Lymph node FNA showing metastatic follicular carcinoma.
Lymph node FNA showing metastatic follicular carcinoma.
Lymph node FNA showing metastatic follicular carcinoma
C1 vertebrae biopsy positive for metastatic follicular carcinoma
C1 vertebrae biopsy positive for metastatic follicular carcinoma
Metastatic follicular carcinoma
Metastatic follicular carcinoma

Metastatic follicular carcinoma